Survec

Nor Q is indicated as an adjunct to general anaesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Nor Q is a non-depolarising muscle relaxants, has an intermediate duration of action. It does not generally produce histamine release and lacks cardiovascular effects. The common side effects of non-depolarising muscle relaxants are skin flushing, hypotension, tachycardia, bronchospasm and very rarely, anaphylactoid reactions. Acute myopathy has also been reported after prolonged use in intensive care.

Allergic cross-reactivity between neuromuscular blocking agents has been reported; caution is advised in cases of hypersensitivity to these drugs. Their activity is prolonged in patients with myasthenia gravis and in hypothermia, therefore lower doses are required. Non-depolarising muscle relaxants should be used with great care in those with other neuromuscular disorders and those with fluid and electrolyte disturbances, as response is unpredictable. Resistance may develop in patients with burns who may require increased doses; low plasma cholinesterase activity in these patients requires dose titration for mivacurium.
General
: Nor Q should be administered in carefully adjusted dosage by or under the supervision of experienced clinicians who are familiar with its actions and the possible complications that might occur following its use. The drug should not be administered unless facilities for intubation, artificial respiration, oxygen therapy, and reversal agents are immediately available. The clinician must be prepared to assist or control respiration. A peripheral nerve stimulator should be employed to monitor drug response, need for additional relaxant, and adequacy of spontaneous recovery or anticholinesterase antagonism.
Intensive Care Unit
: To reduce the possibility of prolonged neuromuscular blockade and other complications that might occur following long-term use in the ICU, Nor Q or any other neuromuscular blocking agent should be administered in carefully adjusted doses by or under the supervision of experienced clinicians who are familiar with its actions and with appropriate peripheral nerve stimulator muscle monitoring techniques.
Neuromuscular Disease
: In patients who are known to have myasthenia gravis or the myasthenic syndrome, small doses of Nor Q may have profound effects. In such patients, a peripheral nerve stimulator and use of a small test dose may be of particular value in assessing and monitoring dosage requirements.

Vecuronium Bromide is a preparation of Vecuronium Bromide. It is a Lyophilized powder for injection. It is a non-depolarising neuromuscular blocking agent. Vecuronium Bromide blocks the transmission process between the motor nerve-ending and striated muscle by binding competitively with acetylcholine to the nicotinic receptors located in the motor end-plate region of striated muscle.